Wondering if BillionToOne is actually worth its triple digit share price, or if the story has simply run ahead of the numbers? This article will unpack what the current price is really implying about its future.

After a volatile spell where the stock dropped 14.2% over the last week but is still up 11.6% over the past month and 2.5% year to date, investors are clearly still trying to decide how much growth and risk to price in.

Recent headlines have focused on BillionToOne's progress in genetic testing and precision diagnostics, with coverage around its expanding test portfolio and growing clinical adoption helping to frame it as a high potential healthcare innovator. These developments have naturally fed into shifting expectations about its long term revenue runway and risk profile, which helps explain the choppy share price action.

Despite the excitement, BillionToOne currently scores just 1/6 on our valuation checks. We will walk through what traditional metrics, cash flow based models and market multiples are really saying about the stock now, before finishing with a more nuanced way to think about valuation that goes beyond the usual playbook.

BillionToOne scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

A Discounted Cash Flow model projects a company’s future cash flows and then discounts those projections back to today, to estimate what the business is worth right now in $ terms.

For BillionToOne, the latest twelve month Free Cash Flow is negative at roughly $14.4 Million, reflecting the company’s ongoing investment phase. Analysts expect this to turn positive and ramp up quickly, with forecasts moving from only single digit Millions in 2026 to around $128 Million of Free Cash Flow by 2029. Beyond those analyst years, Simply Wall St extrapolates the trend, with Free Cash Flow projections reaching roughly $270 Million by 2035.

When all those future $ cash flows are discounted back using a 2 Stage Free Cash Flow to Equity model, the intrinsic value comes out at about $106.45 per share. With the DCF implying the stock is roughly 4.9% overvalued versus the current market price, the model is indicating that most of the anticipated growth is already priced in.

Result: ABOUT RIGHT

BillionToOne is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for BillionToOne.

For high growth healthcare names that are not yet profitable, the Price to Sales ratio is often the cleanest way to compare valuations, because it focuses on what the market is paying for each dollar of current revenue rather than uncertain future earnings.

In theory, faster growth and lower risk justify a higher multiple, while slower or more volatile growth should trade closer to, or even below, the sector norm. Against that backdrop, BillionToOne’s current Price to Sales ratio of roughly 24.25x stands far above the broader Healthcare industry average of about 1.24x, and also well ahead of its more directly comparable peers at around 5.50x. That suggests investors are already pricing in very strong growth and a successful scaling of the business model.

Simply Wall St’s proprietary Fair Ratio metric goes a step further by estimating what a “normal” Price to Sales multiple should be for BillionToOne specifically, after adjusting for its expected revenue growth, margins, risk profile, industry, and market cap. Because the Fair Ratio is tailored to the company’s fundamentals, it may be a more specific guide than simply lining it up against generic sector and peer averages. On this basis, BillionToOne’s current multiple appears significantly above its Fair Ratio, indicating the stock looks overvalued on a sales basis.

Result: OVERVALUED

PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1449 companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple framework that lets you attach a clear story, your assumptions about future revenue, earnings and margins, and a resulting fair value to a company. A Narrative connects three things: what you believe about the business, how that belief translates into a financial forecast, and the fair value that drops out of those numbers. On Simply Wall St, Narratives are an easy to use tool on the Community page, where millions of investors build and share these story plus forecast views so you can see how different perspectives line up against today’s price. By comparing a Narrative’s Fair Value to the current market price, you can quickly see whether your version of the story suggests it is time to buy, hold, or sell, and those views are automatically updated as new news, earnings, or guidance comes in. For example, one BillionToOne Narrative might assume rapid adoption and a high fair value, while another prices in execution risks and sets a much lower fair value, giving you a clear range of possible outcomes to consider.

Do you think there's more to the story for BillionToOne? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BLLN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com